# | Subjects | P-Value ovrlap | Overlap | # | Subjects | P-Value ovrlap | # Molecules |
---|---|---|---|---|---|---|---|
I | Top Canonical Pathways | VII | Cardiotoxicity | ||||
1 | EIF2 Signaling | 1.28E-37 | 30.3 % 67/221 | 31 | Cardiac Infarction | 3.62E-01 - 5.40E-04 | 23 |
2 | Regulation of eIF4 and p70S6K Signaling | 5.38 E-140 | 21.0 % 33/157 | 32 | Caediac Necrosis/Cell Death | 1.65E-01 - 2.56E-03 | 23 |
3 | mTOR Signaling | 1.28 E-13 | 18.4 % 37/102 | 33 | Cardiac Dycfunction | 4.31E-01 - 2.63E-03 | 11 |
4 | B Cell Receptor Signaling | 8.35 E-08 | 14.2 % 27/190 | 34 | Cardiac Fibrosis | 1.77E-01 - 5.68E-03 | 14 |
5 | Signaling | 1.72E-06 | 16.2 % 18/111 | 35 | Cardiac Transformation | 1.10E-02 - 1.10E-02 | 2 |
II | Top Upstream Regulators | Predicted Activation | VIII | Hepatotoxicity | |||
6 | ST 1926 | 5.62E-20 | Activated | 36 | Liver Proliferation | 2.15E-01 - 5.85E-05 | 26 |
7 | Sirolimus | 2.32E-18 | Activated | 37 | Liver Necrosis/Cell Death | 6.13E-01 - 6.59E-05 | 29 |
8 | CD 437 | 1.45E-17 | Activated | 38 | Liver Damage | 4.69E-01 - 1.81E-04 | 35 |
9 | RICTOR | 1.64E-17 | Activated | 39 | Liver Inflamma/Hepatitistion | 4.52E-01 - 5.02E-04 | 36 |
10 | MYCN | 3.22E-15 | Inhibited | 40 | Liver Cirrhosis | 4.19E-02 - 1.65E-03 | 21 |
III | Diseases and Disorder | # Molecules | IX | Nephrotoxicity | |||
11 | Infectious Diseases | 1.14E-04 - 1.29E-24 | 244 | 41 | Renal Necrosis/Cell Death | 3.32E-01 - 7.15E-05 | 46 |
12 | Immunological Disease | 7.41E-05 - 2.37E-23 | 372 | 42 | Renal Inflammation | 3.74E-01 - 1.69E-03 | 33 |
13 | Cancer | 1.25E-04 - 4.75E-22 | 839 | 43 | Renal Nephritis | 3.70E-01 - 1.69E-03 | 33 |
14 | Organismal Injury and Abnormalities | 1.36E-04 - 4.75E-21 | 865 | 44 | Renal Damage | 5.15E01 - 3.12E-03 | 21 |
15 | Tumor Morphology | 1.19E-04 - 4.75E-21 | 82 | 45 | Glomerular Injury | 1.00E-00 - 1.47E-02 | 22 |
IV | Molecular and Cellular Functions | # Molecules | X | Top Regulator Effect Networks | Disease & Functions | Consistency Score | |
16 | Cellular Development | 1.24E-04 - 1.29E-24 | 222 | 46 | Ap1,CAMP,F2RL1,IL17A,IL1RN,KITLG,mir10,NRG1,SELP (+2 >) | Activationof antigen presenting cells (+11 >) | 40.848 |
17 | Cellular Growth and Proliferation | 1.24E-04 - 1.29E-24 | 206 | 47 | AP1,CAMP,EIF2AK2,F2RL1,IL17A,IL1RN, KITLG (+2 >) | Activationof phagocytes (+9 >) | 36.338 |
18 | Cell Death and Survival | 1.36E -04 - 3.94E-21 | 371 | 48 | 26s Proteasome,ANGPT2,AP1,BCL2,CAMP,CEBPA,F2RL (+6 >) | Activationof antigen presenting cells (+10 >) | 32.199 |
19 | Cell-To-Cell Signalingand Interaction | 1.34EE-18-04 - 7.04 | 183 | 49 | 26s Proteasome,CAMP,CSF1,IL17A,JUN,LDL (+5 >)F2RL (+6 >) | Activationof antigen presenting cells (+7 >) | 30.414 |
20 | Cellular Function and Maintenance | 1.02E-04 - 2.10E-16 | 232 | 50 | AP1,CAMP,CCL5,EIF2AK2,F2RL1,FGF10,IL17A,IL1RN (+5 >) | Accumulation of leukocytes (+19 >) | 30.375 |
V | Physiological System Development and Function | # Molecules | XI | Top Networks (Associated Network Functions) | Score | ||
21 | Hematological System Development and Function | 1.34E-04 -1.29E-24 | 255 | 51 | Developmentall Disorder, Hereditary Disorder, Metabolic Diseases | 46 | |
22 | Lymphoid Tissue Structure and Development | 1.33E-04 -1.29E-24 | 194 | 52 | Cancer, Cell Death and Survival, Organismal Injury and Abnormalities | 44 | |
23 | Tissue Morphology | 1.19E-04 - 2.45E-19 | 184 | 53 | Post-Translational Midification, Cell Cycle, Cellular Development | 44 | |
24 | Immune Cell Trafficking | 1.34E-04 - 7.04E-18 | 160 | 54 | Cancer, Hematological Disease, Immunological Disease | 41 | |
25 | Hematopoiesis | 1.02E004 - 6.87E-14 | 130 | 55 | Protein Synthesis, RNA Post-Transcriptional Modification, Gene Expression | 39 | |
VI | Top Tox Functions (Clinical Chemistry and Hematology) | # Molecules | XII | Top Toxicology Lists | p-value | Overlap | |
26 | Increased Levels of Albumin | 2.38E-01 - 1.24E-02 | 4 | 56 | Renal Necrosis/Cell Death | 1.58E-05 | 8.60 % 46/538 |
27 | Increased Levels of Alkaline Phosphatase | 2.12E-01 - 4,42E-02 | 6 | 57 | Liver Prolification | 1.80E-05 | 11.0 % 26/236 |
28 | Decreased Levels of Hematocrit | 5.71E-02 - 5.71E-02 | 2 | 58 | Liver Necrosis/ Cell Death | 8.35E-05 | 9.6 % 29/303 |
29 | Increased Levels of Hematocrit | 6.20E-02 - 6,20E-02 | 8 | 59 | Mechanism of Gene regulation by Peroxisome | 2.74E-04 | 13.7 % 13/95 |
30 | Increased Levels of Potassium | 5.36E-01 - 8.64E-02 | 2 | 60 | Increases Liver Damage | 7.40E-04 | 11.4 % 15/132 |
A | Gene Expression Fold Change (Up-regulated) | Expression Value | B | Gene Expression Fold Change (Down-regulated) | Expression Value | ||
1 | SNORD15A | 581.151 | 1 | HMGN1P3 | -381.06 | ||
2 | SNORA32 | 390.353 | 2 | SNHG25 | -350.0555 | ||
3 | SNORA56 | 185.194 | 3 | SNORA67 | -148.69 | ||
4 | SNORA9 | 124.698 | 4 | RPL17-C18orf32 | -67.253 | ||
5 | SNORS3B | 102.91 | 5 | ISY1-RAB43 | -51.147 | ||
6 | SNORA3A | 93.09 | 6 | ARHGEF18 | -41.381 | ||
7 | HIST1H2AD | 20.784 | 7 | KLRC4-KLRK1/KLK1 | -20.578 | ||
8 | SNORD3D | 17.157 | 8 | HIST1H3J | -19.795 | ||
9 | LINC00305 | 4.853 | 9 | MTHFS | -18.71 | ||
10 | HHIPL2 | 4.844 | 10 | SNORA16A | -18.285 |